This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bellahcene, A. Articles by Castronovo, V. Search for Related Content PubMed PubMed Citation Articles by Bellahcene, A. Articles by Castronovo, V.

American Journal of Pathology, Vol 146, 95-100, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer

A Bellahcene and V Castronovo
Metastasis Research Laboratory, University of Liege, Belgium.

Microcalcifications are a common phenomenon associated with breast cancer and are often the only mammographic sign of a malignant breast disease. Although microcalcifications are not restricted to breast cancer and can be also associated with benign lesions, it is noteworthy that they are composed exclusively of hydroxyapatite in breast carcinoma. Hydroxyapatite is the bone-associated phosphocalcic crystal the deposition of which in bone tissue requires the coordinated expression of several molecules such as osteonectin (OSN) and osteopontin (OPN), synthesized by cells of the osteoblastic lineage. In this study, we evaluated the expression of these two bone matrix proteins, using an immunoperoxidase technique and specific antibodies, in 79 breast lesions including 28 benign and 51 cancerous specimens. We found that normal mammary tissue associated with the lesions examined expressed generally undetectable or lightly detectable (0 or 1+) amounts of OSN and OPN (92 and 81%, respectively). Benign breast lesions, including fibroadenoma and fibrocystic dysplasia, were generally weakly stained (0 or 1+) with both anti-OSN and anti-OPN antibodies (96.4 and 60.7%, respectively). Interestingly, the majority of both in situ and invasive breast carcinoma lesions showed a strong expression (2+ or 3+) for OSN or OPN (74.5 and 84.3%, respectively). High expression of these two bone matrix proteins was associated with frequent microcalcification deposition in the lesion. This study is the first extensive study of OSN and OPN expression in mammary cancers. Our data suggest that OSN and OPN could play a role in the formation of ectopic microcalcifications often associated with breast cancer. It is also tempting to speculate that the expression of these two glycoproteins by breast cancer cells play a role in the preferred bone homing of breast metastases.

This article has been cited by other articles:

				P.-L. Chang, L. Harkins, Y.-H. Hsieh, P. Hicks, K. Sappayatosok, S. Yodsanga, S. Swasdison, A. F. Chambers, C. A. Elmets, and K.-J. Ho Osteopontin Expression in Normal Skin and Non-melanoma Skin Tumors J. Histochem. Cytochem., January 1, 2008; 56(1): 57 - 66. [Abstract] [Full Text] [PDF]

				K. U.E. Ogbureke and L. W. Fisher SIBLING Expression Patterns in Duct Epithelia Reflect the Degree of Metabolic Activity J. Histochem. Cytochem., April 1, 2007; 55(4): 403 - 409. [Abstract] [Full Text] [PDF]

				N. Said, I. Najwer, and K. Motamed Secreted Protein Acidic and Rich in Cysteine (SPARC) Inhibits Integrin-Mediated Adhesion and Growth Factor-Dependent Survival Signaling in Ovarian Cancer Am. J. Pathol., March 1, 2007; 170(3): 1054 - 1063. [Abstract] [Full Text] [PDF]

				V. H.C. Bramwell, G. S. Doig, A. B. Tuck, S. M. Wilson, K. S. Tonkin, A. Tomiak, F. Perera, T. A. Vandenberg, and A. F. Chambers Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3337 - 3343. [Abstract] [Full Text] [PDF]

				J. E. Koblinski, B. R. Kaplan-Singer, S. J. VanOsdol, M. Wu, J. A. Engbring, S. Wang, C. M. Goldsmith, J. T. Piper, J. G. Vostal, J. F. Harms, et al. Endogenous Osteonectin/SPARC/BM-40 Expression Inhibits MDA-MB-231 Breast Cancer Cell Metastasis Cancer Res., August 15, 2005; 65(16): 7370 - 7377. [Abstract] [Full Text] [PDF]

				J. N. Rich, C. Hans, B. Jones, E. S. Iversen, R. E. McLendon, B.K. A. Rasheed, A. Dobra, H. K. Dressman, D. D. Bigner, J. R. Nevins, et al. Gene Expression Profiling and Genetic Markers in Glioblastoma Survival Cancer Res., May 15, 2005; 65(10): 4051 - 4058. [Abstract] [Full Text] [PDF]

				S. Schneider, J. Yochim, J. Brabender, K. Uchida, K. D. Danenberg, R. Metzger, P. M. Schneider, D. Salonga, A. H. Holscher, and P. V. Danenberg Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1588 - 1596. [Abstract] [Full Text] [PDF]

				G. L. Barnes, A. Javed, S. M. Waller, M. H. Kamal, K. E. Hebert, M. Q. Hassan, A. Bellahcene, A. J. van Wijnen, M. F. Young, J. B. Lian, et al. Osteoblast-related Transcription Factors Runx2 (Cbfa1/AML3) and MSX2 Mediate the Expression of Bone Sialoprotein in Human Metastatic Breast Cancer Cells Cancer Res., May 15, 2003; 63(10): 2631 - 2637. [Abstract] [Full Text] [PDF]

				A. Chlenski, S. Liu, S. E. Crawford, O. V. Volpert, G. H. DeVries, A. Evangelista, Q. Yang, H. R. Salwen, R. Farrer, J. Bray, et al. SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis Cancer Res., December 15, 2002; 62(24): 7357 - 7363. [Abstract] [Full Text] [PDF]

				C. A. Iacobuzio-Donahue, P. Argani, P. M. Hempen, J. Jones, and S. E. Kern The Desmoplastic Response to Infiltrating Breast Carcinoma: Gene Expression at the Site of Primary Invasion and Implications for Comparisons between Tumor Types Cancer Res., September 15, 2002; 62(18): 5351 - 5357. [Abstract] [Full Text] [PDF]

				P. S. Rudland, A. Platt-Higgins, M. El-Tanani, S. de Silva Rudland, R. Barraclough, J. H. R. Winstanley, R. Howitt, and C. R. West Prognostic Significance of the Metastasis-associated Protein Osteopontin in Human Breast Cancer Cancer Res., June 1, 2002; 62(12): 3417 - 3427. [Abstract] [Full Text] [PDF]

				S. R. Rittling, Y. Chen, F. Feng, and Y. Wu Tumor-derived Osteopontin Is Soluble, Not Matrix Associated J. Biol. Chem., March 8, 2002; 277(11): 9175 - 9182. [Abstract] [Full Text] [PDF]

				G. K. Yiu, W. Y. Chan, S.-W. Ng, P. S. Chan, K. K. Cheung, R. S. Berkowitz, and S. C. Mok SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells Am. J. Pathol., August 1, 2001; 159(2): 609 - 622. [Abstract] [Full Text]

				I. H. N. Wong, A. T. Chan, and P. J. Johnson Quantitative Analysis of Circulating Tumor Cells in Peripheral Blood of Osteosarcoma Patients Using Osteoblast-specific Messenger RNA Markers: A Pilot Study Clin. Cancer Res., June 1, 2000; 6(6): 2183 - 2188. [Abstract] [Full Text]

				R. Thomas, L. D. True, J. A. Bassuk, P. H. Lange, and R. L. Vessella Differential Expression of Osteonectin/SPARC during Human Prostate Cancer Progression Clin. Cancer Res., March 1, 2000; 6(3): 1140 - 1149. [Abstract] [Full Text]

				S. A. Rempel, S. Ge, and J. A. Gutierrez SPARC: A Potential Diagnostic Marker of Invasive Meningiomas Clin. Cancer Res., February 1, 1999; 5(2): 237 - 241. [Abstract] [Full Text] [PDF]

				D.N.S Kerr Hypercalcemia and metastatic calcification Cardiovasc Res, December 1, 1997; 36(3): 293 - 297. [Full Text] [PDF]